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Review article
IgA vasculitis, formerly known as Henoch-Schönlein purpura, 
is a systemic IgA-mediated vasculitis of the small vessels com-
monly seen in children. The natural history of IgA vasculitis is 
generally self-limiting; however, one-third of patients experi-
ence symptom recurrence and a refractory course. This syste-
matic review examined the use of dapsone in refractory IgA 
vasculitis cases. A literature search of PubMed databases retriev-
ed 13 articles published until June 14, 2018. The most common 
clinical feature was a palpable rash (100% of patients), followed 
by joint pain (69.2%). Treatment response within 1–2 days was 
observed in 6 of 26 patients (23.1%) versus within 3–7 days in 
17 patients (65.4%). Relapse after treatment discontinuation 
was reported in 17 patients (65.4%) but not in 3 pati ents (11.5 
%). Four of the 26 patients (15.4%) reported ad verse effects of 
dapsone including arthralgia (7.7%), rash (7.7%), and dapsone 
hypersensitivity syndrome (3.8%). Our findings suggest that 
dapsone may affect refractory IgA vasculitis. Multi center ran-
domized placebo-controlled trials are necessary to determine 
the standard dosage of dapsone at initial or tapering of treatment 
in IgA vasculitis patients and evaluate whether dapsone has a 
significant benefit versus steroids or other medi cations.
Keywords: IgA vasculitis, Henoch-Schonlein purpura, Dap-
sone, Systematic review
Key message
Question: Is dapsone effective in reftractory IgA vasculitis?
Finding: Treatment response within 7 days was observed in 
88.5% patients. Treatment discontinuation without tapering 
seems related to relapse because 15 patients reported prompt 
recurrence, whereas the tapering group reported fewer re-
lapses than without tapering.
Meaning: Multicenter randomized placebo-controlled trials 
are necessary to determine the standard dosage of dapsone at 
initial or tapering of treatment in IgA vasculitis with cautions 
of side effects.
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Introduction
IgA vasculitis, formerly known as Henoch-Schönlein purpura, 
is a systemic IgA-mediated vasculitis of the small vessels that is 
common in children. The major clinical features of IgA vasculitis 
are palpable purpura, arthritis, abdominal pain, and nephritis.1) 
The natural history of IgA vasculitis is generally self-limiting; 
however, one-third of patients experience symptom recurrence 
and a refractory course.2) Patients with renal disease are more 
likely to experience recurrence, and the long-term prognosis of 
IgA vasculitis is related to nephritis.1-5)
However, the treatment for IgA vasculitis has not been 
established. Steroids can manage abdominal pain symptoms but 
are unsuitable for the prevention of nephropathy.2) Joint pain is 
managed with nonsteroidal anti-inflammatory drugs and steroids 
in severe cases.2) Cutaneous symptoms respond to steroids and 
dapsone.2) Some studies reported that immunosuppressive 
therapy could be considered for IgA vasculitis with nephropathy; 
however, the treatment of nephritis remains controversial.2) 
Treatment with steroids and immunosuppressive therapy such as 
cyclophosphamide, cyclosporine, and azathioprine is beneficial 
for IgA vasculitis nephritis.1,2,6) Some reports showed that 
colchicine and dapsone may be useful for treating chronic IgA 
vasculitis.6)
Among the diverse armamentarium of therapeutic options, 
dapsone has been used in several severe cases. Although it is not 
considered a standard treatment for IgA vasculitis, purpuric 
rash, abdominal pain, and arthritis in IgA vasculitis respond to 
it.7) Dapsone, known as an antileprosy drug, has antioxidant 
scavenger effects and may suppress the production of toxic free 
radicals by neutrophils. It also inhibits prostaglandin D2 produc-
tion and the synthesis of IgG and IgA antibodies.8) It also inhibits 
IgA-neutrophil interactions, which may explain the potential 
efficacy of dapsone in the management of IgA vasculitis.7,9) 
Therefore, in the absence of clinical trials, this systematic review 
aimed to elucidate the characteristics of dapsone use in refractory 
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We searched PubMed for articles of IgA vasculitis treated with 
dapsone published until June 14, 2018. The search terms were: 
“Purpura” AND “Dapsone”. Two of the reviewers (SHH and 
YHJ) screened the articles by reading the titles, abstracts, and full 
texts.
The exclusion criteria were as follows:
(1) studies not related to IgA vasculitis or dapsone; (2) studies 
not written in English; (3) review articles; (4) animal studies; and 
(5) studies that are considered too old to be reliable.
One reviewer (SHH) executed the initial search, which re-
trieved 99 articles published until June 24, 2015. Identification 
of the relevant literature was performed according to the 
PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-analyses) statement.10) We excluded 86 articles after 
reading the abstracts and full texts according to the exclusion 
criteria stated above: 60 not about IgA vasculitis or dapsone, 
13 not written in English, 11 were review articles, and 2 were 
animal studies. Of the remaining 13 articles, 1 that was published 
in 1973 was excluded because we considered it too old to be 
reliable. After about 3 years, another reviewer (YHJ) conducted 
the following search that retrieved 10 more articles published 
until June 14, 2018. Of those 10 articles, 9 not related to IgA 
vasculitis or dapsone were excluded. Finally, 13 articles eligible 
for our systematic review were identified (5 case reports, 3 case 
series, and 5 letters). All these studies were defined “refractory” 
IgA vasculitis and “positive response” to dapsone. The detailed 
process of article selection is presented in Fig. 1. The detailed 
article selection process is presented in Fig. 1.
2. Data extraction
From the 13 articles, 2 reviewers (SHH and YHJ) extracted 
the data and organized the information including author names, 
journal title, patient age and sex, dosage, clinical features, treat-
ment response, treatment duration, postdischarge relapse, and 
adverse effects. When discrepancies arose, 2 reviewers (JIS and 
KHL) discussed them until a consensus was reached.
3. Data analysis
The data extracted from the articles are presented in Table 1.7-
9,11-18) We organized the information including the patient age 
and sex, clinical presentation, dosage, treatment response time, 
treatment response, treatment duration, postdischarge relapse, 
and adverse effects for analyses (Tables 2, 3).7-9,11-18)
Results
1. Presenting features of IgA vasculitis patients
Data of 26 patients with IgA vasculitis were selected from 11 
articles; their clinical features are described in Table 1. The mean 
patient age was 21.98 years; 14 cases were pediatric. The male-
female ratio was 9:4 (18:8).
The most common clinical feature, a palpable rash, was seen in 
all 26 patients. Joint pain was the second most common feature 
(18 of 26 patients; 69.2%). Other commonly reported features 
were abdominal pain in 16 patients (61.5%) and hematuria in 10 
patients (38.5%). Joint swelling was reported in 8 patients (30.8 
%); 6 patients (23.1%) also had joint pain. Two patients (8.0%) 
without joint pain were female and younger than 15 years of age. 
Seven patients (26.9%) had vomiting. Proteinuria was identified 
in 6 patients (23.1%); all but 1 patient also had hematuria. Pati-
ents with proteinuria were all younger than 15 years old. Five 
patients had diarrhea, while all had joint pain. Every patient with 
vomiting and diarrhea complained of abdominal pain. Three 
patients (11.5%) had rectal bleeding; all were younger than 15 
years of age. The bleeding was associated with hematuria and 
joint pain. Only 1 patient had a swollen testicle. Bullae and ulcers 
were simultaneously seen in 2 patients (8.0%).
Table 2 summarizes the results of 26 dapsone-treated IgA vas-
culitis patients by age, sex, dapsone dosage, symptom course, 
and adverse effects. We describe specific dapsone dosages, clini-
cal outcomes, and adverse effects of dapsone in this section.
2. Dapsone dosage
All patients were grouped by age. Patients in group 1 were 
11–56 years, while those in group 2 were 2–10 years. Age was 
factored into the dapsone dosing strategies; the results due to 
99 Articles reviewed by screening
82 Articles were excluded
57 were not about IgA vasculitis or dapsone
13 were not written in English
10 review article  
2 were animal studies
17 Articles reviewed by abstract screening
2 Articles were excluded
15 Articles reviewed by full text screening
3 Articles were excluded
1 were review articles
1 were not about IgA vasculitis or dapsone





10 More articles were published until June 14, 2018





(published until June 14, 2018)
Fig. 1.  Flow chart of literature search.
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1 Jayavardhana12) 11/F 　 + 　 　 　 　 　 　 　 　 　 　 　
2 Bech13) 21/F 　 + 　 　 　 　 　 　 　 　 　 　 　
3 Papandreou7) 13/M 　 + 　 　 + 　 　 　 + + 　 　 　
4 Shimomura14) 28/M 　 + + 　 + 　 　 　 　 　 　 　 　
5 Ramelli15) 13/F 　 + + + 　 　 　 　 + + 　 　 　
6 Ledermann11) 33/M 　 + + + + 　+ 　+ 　 + 　 　 　 　
7 Iqbal9) 2/F + + 　 + 　 　 　 　 　 　 　 　 　
8 Iqbal9) 8/F 　 + + 　 　 　 　 　 + + + 　 　
9 Iqbal9) 8/F 　 + + + + 　 　 　 + + 　 　 　
10 Iqbal9) 5.5/M 　 + 　 　 +   + 　 + 　 　 　 　 　
11 Iqbal9) 10/F 　 + + + 　 　 　 　 + 　 + 　 　
12 Iqbal9) 5/F 　 + + + +   + 　 　 　 + 　 　 　
13 Iqbal9) 8/M 　 + 　 　 +   + 　 　 + + 　 　 　
14 Iqbal9) 10/F 　 + + 　 　 　 　 　 + 　 + 　 　
15 Sarma16) 18/F 　 + + 　 + 　 　 　 　 　 　 　 　
16 Sarma16) 22/F 　 + + 　 +   + 　 　 　 　 　 　 　
17 Sarma16) 32/M 　 + + 　 +   +   + 　 + 　 　 　 　
18 Sarma16) 47/F 　 + + 　 + 　   + 　 　 　 　 　 　
19 Sarma16) 54/F 　 + + 　 + 　   + 　 + 　 　 　 　
20 Sarma16) 48/F 　 + + 　 + 　 　 　 　 　 　 　 　
21 Hoffbrand17) 24/M 　 + + + + 　 　 　 　 　 　 　 　
22 Hoffbrand17) 15/M 　 + + 　 +   +   + 　 　 　 　 　 　
23 Fredenberg8) 56/F 　 + 　 　 　 　 　 　 　 　 　 　 　
24 Fredenberg8) 15/F 　 + 　 + 　 　 　 　 　 　 　 　 　
25 Fredenberg8) 51/F 　 + + 　 　 　 　 　 　 　 　 + +
26 Chen18) 14/F 　 + + 　 　 　 　 　 　 　 　 + +


























of ankle pain 
(n=7)
1 Jayavardhana12) 11/F 50 　 ~1 Yes 　 2 Wk 　 DHS
2 Bech13) 21/F 100 　 ~1 Yes 　 7 Day Prompt 　
3 Papandreou7) 13/M 100a) 1.2 Prompt Yes 　 Yes 　 Prompt 　
4 Shimomura14) 28/M 50 　 ~Few weeks 　 Yesb) 1 Wk 3 Yr 　
5 Ramelli15) 13/F 　 1.2 ~3 Yes 　 Yes 　 Prompt Arthralgia
6 Ledermann11) 33/M 100 　 2 Yes 　 6 Mo Prompt Rash, arthralgia, GI symptoms
7 Iqbal9) 2/F 　 1 3~7 　 Yes 6 Day No 　
8 Iqbal9) 8/F 　 1.3 3~7 　 Yes 7 Day Prompt 　
9 Iqbal9) 8/F 　 1 3~7 　 Yes 4 Day No 　
10 Iqbal9) 5.5/M 　 1.25 3~7 　 Yes 2.5 Yr Prompt 　
11 Iqbal9) 10/F 　 0.75 3~7 　 Yes 8 Mo Prompt 　
12 Iqbal9) 5/F 　 1 3~7 　 Yes 35 Day Prompt 　
13 Iqbal9) 8/M 　 1 3~7 　 Yes 35 Day Prompt 　
14 Iqbal9) 10/F 　 0.5 3~7 　 Yes 2 Yr Prompt 　
15 Sarma16) 18/F 100 　 3 Yes 　 Yes 2 Mo Prompt 　
16 Sarma16) 22/F 100 　 3 Yes 　 Yes 1 Mo No 　
17 Sarma16) 32/M 100 　 4 Yes 　 Yes 2 Mo Prompt 　
18 Sarma16) 47/F 100 　 3 Yes 　 Yes 2 Mo Prompt 　
19 Sarma16) 54/F 100 　 4 Yes 　 Yes 4 Mo Prompt 　
20 Sarma16) 48/F 100 　 4 Yes 　 Yes 4 Mo Prompt 　
21 Hoffbrand17) 24/M 100 　 ~1 Yes 　 60 Day 1 Yrc) 　
22 Hoffbrand17) 15/M 50 　 ~0.125 　 　 Yes 7 Day 　
23 Fredenberg8) 56/F 75, 100 　 ~7 Yes 　 30 Day 4–5 Day Dizziness
24 Fredenberg8) 15/F 50, 100, 150 　 8 Yes 　 16 Mo 　
25 Fredenberg8) 51/F 100 　 4 Yes 　 8 Mo 　
26 Chen18) 14/F 25, 50 　 5 　 Yes 　 6 Mo 　
Tx., treatment; DHS, dapsone hypersensitivity syndrome; GI, gastrointestinal.
a)With prednisolone 2 mg/kg/day. b)Purpura resolved gradually with the combination of factor XIII. c)Occasional relapses over the following 10 months. 
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different strategies from the 2 groups are summarized in Table 
4. The doses given to each patient with IgA vasculitis differed 
widely. Daily doses of 50–100 mg  were administered in group 
1, while daily doses of 0.50–1.30 mg/kg were administered in 
group 2.
In group 1, 11 patients took 100 mg dapsone per day and 
4 patients took 50 mg per day. One patient in group 1 (not 
shown in Table 4) received a prescribed dapsone dose in units of 
milligrams per kg. Another patient in group 1 started on dapsone 
75 mg every day, but it was increased to 100 mg after 3 days. In 
group 2, 4 of 8 patients took dapsone 1 mg/kg, and the other 4 
patients were administered different doses of 0.5, 0.75, 1.25, 
and 1.30 mg/kg.
3. Symptom course
Symptom resolution was reported in all cases. Table 3 shows 
the patients’ treatment responses time, extent of response, and 
time to relapse after discontinuation. Treatment response within 
1–2 days was observed in 6 of the 26 patients (23.1%). Within 
3–7 days, 17 patients (65.4%) responded to treatment. Three 
patients (11.5%) showed a response after the first week.
Symptom improvements were categorized as follows: disap-
pearance of purpura, positive response to dapsone, disappear-
ance of abdominal pain, and disappearance of ankle pain. Of the 
26 patients, 14 (57.7%) showed disappearance of purpura, 10 
patients (38.5%) showed a positive response, 3 patients (11.5%) 
reported disappearance of abdominal pain, and 7 patients (26.9 
%) reported disappearance of ankle pain.
Relapse after treatment discontinuation was reported in 17 
patients (65.4%), whereas 3 patients (11.5%) reported no re lapse 
of symptoms. Six patients’ follow-up data regarding symp tom 
relapse could not be obtained. Of the 17 patients who showed 
symptom relapse, immediate relapse after therapy discontinua-
tion was reported in 10 patients (58.8%), relapse within 1 year 
was reported in 4 patients (23.5%), and relapse beyond 1 year 
after discontinuation was reported in 3 patients (17.6%).
In the immediate relapse group, all but 1 patient showed im-
mediate symptom recurrence after discontinuation and 1 patient 
reported relapse of symptoms 4–5 days after disconti nuation. 
Of the 4 patients who experienced relapse during the first year, 
1 reported occasional relapse during the first 10 months, while 
the other 3 patients showed no recurrence within 6, 9, and 12 
months after discontinuation. Of the 3 patients who showed 
relapse after 1 year, 1 patient reported purpura and mild arthral-
gia after 3 years. The other 2 patients had disease-free periods of 
1.5 and 6 years (Table 3).
4. Adverse effects of dapsone
Four of the 26 patients (15.4%) reported adverse effects of 
dapsone. The adverse effects are summarized in Table 5. The 
adverse effects of dapsone for patients with IgA vasculitis in-
cluded arthralgia (7.7%), dapsone hypersensitivity syndrome 
(3.8%), rash (7.7%), gastrointestinal symptoms (3.8%), and 
dizziness (3.8%). Only 1 patient reported multiple adverse effects 
including arthralgia, rash, and gastrointestinal symptoms.
Discussion
IgA vasculitis is a systemic IgA-mediated vasculitis charac-
terized by palpable cutaneous purpura, arthritis, abdominal pain, 
gastrointestinal bleeding, and nephritis.1) Although IgA vasculitis 
is usually a self-limiting disease, one report showed that 33% 
of patients experience a relapse.19) The aim of drug therapy in 
IgA vasculitis is rapid symptomatic relief because the symptoms 
of IgA vasculitis are generally self-limiting with the exception of 
renal disease, which might become a long-term complication.1) 
Steroids are considered the mainstay of treatment because they 
seem to have a relief effect on abdominal20,21) and joint pain.21) In 
Table 3. Symptom course of patients with IgA vasculitis
Course of symptoms
Treatment response
1–2 Days 3–7 Days >7 Days
Disappearance of purpura (n=15) 5a) 9 1
Positive response (n=10) - 9b) 1c)
Disappearance of abdominal pain (n=3) 2d) 1 -
Disappearance of ankle pain (n=7) 1 6 -
Relapse after discontinuation Immediate ≤1 Year >1 Year
Relapsed (n=17) 10e) 4f) 3g)
No relapse (n=3) - - -
a)One with prednisone 2 mg/kg/day. b)With the most beneficial effect on 
the skin rash. c)One with purpura resolved gradually with the combination 
of factor XII. d)One with no information about the exact time of the disap-
pearance of purpura. e)Prompt relapse (n=9), relapse after 4–5 days (n=1). 
f)Occasional relapse over 10 months (n=1), No recurrence for 9 months 
(n=1), no recurrence. for 6 months, No recurrence for 12 months with 50 
mg as maintenance therapy (n=1). g)Purpura and mild arthralgia without 
abdominal pain in 3 years (n=1), 6-year disease free (n=1), 1.5-year disease 
free (n=1).
Table 4. Dapsone dosages for patients with IgA vasculitis
Variable
Duration of treatment (day)
Group 1 Group 2








75 mg/day  1a)
100 mg/day 11
a)Increased to 100 mg/day after 3 days.
Table 5. Adverse effects of dapsone for patients with IgA 
vasculitis
Adverse effectsa) Arthralgia DHS Rash GI symptoms Dizziness
No. of patients 2 1 2 1 1
DHS, dapsone hypersensitivity syndrome; GI, gastrointestinal.
a)Patient showed arthralgia, rash, GI symptoms altogether. 
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one study of 417 patients, corticosteroids and nonsteroidal anti-
inflammatory drugs were commonly prescribed.22) One report 
showed that azathioprine can be used to treat recurrent IgA 
vasculitis.23) Factor XIII may have diagnostic value in patients 
with severe gastrointestinal symptoms without cutaneous rash; 
the infusion of activated factor XIII can be an adjunctive therapy 
in such patients.24) Similarly, factor XIII and intravenous immu-
noglobulin therapy can be effective in IgA vasculitis patients with 
severe abdominal symptoms.25,26)
Despite various attempts, a standardized treatment for re-
current IgA vasculitis is lacking. Corticosteroids have various 
side effects; corticosteroid-resistant patients with IgA vasculitis 
have been treated effectively with mizoribine or cyclosporine 
A.27,28) Drugs such as azathioprine, factor XIII, and intravenous 
immunoglobulin are expensive or exhibit potential severe side 
effects. In contrast, dapsone is safe and available in pill form. 
However, only a few cases of recurrent IgA vasculitis were treat-
ed with dapsone.
The use of dapsone in IgA vasculitis appears rela tively unfa-
miliar to clinicians compared to that of steroids, although the 
first case of IgA vasculitis treated with dapsone was reported in 
1983.29) Dapsone is an antileprosy drug that can be used for der-
matological diseases associated with the deposition of antibodies 
and accumulation of neutrophils.30) Dapsone is an alter native, 
especially in relapsed IgA vasculitis, considering that IgA vas-
culitis is an IgA-mediated vasculitis and that the IgA-neutrophil 
interaction could be inhibited by dapsone.7,9)
The World Health Organization (WHO) regimens are the 
standard treatment for leprosy. The WHO recommends using 
dapsone 100 mg daily for 6 months in cases of paucibacillary 
leprosy and 100 mg daily for at least 2 years and to smear 
negativity in cases of multibacillary leprosy.30) One study showed 
that peak serum concentrations of dapsone of 1.10–2.33 mg/L 
were reached within 0.5–4 hours after 100 mg was orally 
administered to 25 healthy volunteers.31) However, in severe 
leprosy patients, absorption could be decreased.32) In leprosy, the 
therapeutic range of dapsone is 0.5–5 mg/L; the adverse effect 
of dapsone is rare at plasma levels below 5 mg/L.33) The most 
common adverse effect is methemoglobinemia, which is usually 
not a serious problem except at doses exceeding 200 mg/day.34) 
Hemolysis and frank anemia is another well-known side effect.35) 
Increasing age and the daily dose of dapsone were related to 
increased magnitude of hemolysis in dapsone therapy.35) Thus, it 
is recommended not to exceed 1.5 mg/kg body weight or 100 mg 
in normal healthy persons.36) Agranulocytosis is a fatal adverse 
effect of dapsone.37) Another rare side effect is a hypersensitivity 
syndrome, called dapsone syndrome, which is characterized 
by fever, rash, and internal organ involvement.38,39) Other side 
effects include neurotoxicity such as peripheral neuropathy (rare, 
typically at doses exceeding 300 mg/day) and psychosis (rare, at 
doses below 100 mg/day), which is dose-independent.40-43)
In our reviewed patients, no treatment exceeded 100 mg/
day or 1.5 mg/kg. One patient who stopped dapsone because 
of dizziness at 100 mg/day did not report dizziness at 150 mg/
day after IgA vasculitis recurrence. This means that the side effect 
of dapsone is somewhat unpredictable and dose-independent. 
However, although many side effects of dapsone may be dose-
independent, to minimize the adverse effect, the dose should 
not exceed 100 mg/day or 1.5 mg/kg. In our reviewed patients, 
treatment discontinuation without tapering seems related 
to relapse because 15 patients reported prompt recurrence, 
whereas the tapering group reported fewer relapses.
This study has the limitation that only 26 patients were re-
viewed. Because of the small number of patients, it is difficult to 
explain the use of dapsone in detail such as how to taper its use. 
Of our reviewed patients, 19.0% did not require dose tapering; 
however, because of the small number of patients, our results 
cannot confirm what percentage of people will need it or why.
To best of our knowledge, this is the first systematic review 
to summarize the efficacy of dapsone in IgA vasculitis. Since se-
veral side effects should be noted, most patients with recurrent 
or refractory disease should be counseled about the side effects 
by clini cians and start on dapsone according to the risks and 
benefits. However, our study will increase awareness that dap-
sone is an effective treatment for recurrent IgA vasculitis pati ents. 
Multicenter randomized placebo-controlled clinical trials are 
necessary to determine the standard dapsone use or dosage as a 
treatment option at the time of treatment initiation or tapering 
in refractory IgA vasculitis patients and evaluate whether it has 
a significant benefit compared to steroids or other medications.
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